Revolutionising Medicines Manufacturing Takes Serious Collaboration Feature session - Hosted by CPI

Time & Location

Wednesday: 11.00 to 12.00, Stage 3

Hosted by CPI

Dr. Neil SheddanBusiness Development Director, Medicines Manufacturing Innovation Centre at CPI

About this Session


Revolutionising Medicines Manufacturing Takes Serious Collaboration Feature session

If partnering has crossed your mind when looking at ways to accelerate your innovation but don’t know where to start, come along to learn how CPI is leveraging the power of partnerships to overcome some of the challenges

to successful collaboration. Through a Grand Challenge model, aimed at tackling the pharmaceutical industry’s largest problems, CPI’s Medicines

Manufacturing Innovation Centre is working together with collaborators in a pre-competitive environment, to break down barriers previously limiting the ability and speed of new and innovative technology adoption.

Session coordinator: Dr. Neil Sheddan, Business Development Director, Medicines Manufacturing Innovation Centre at CPI

Speakers /Panellists include:

CPI Pharma Capability Overview:

  • Dr. Sam Neill, Business Development Director – CPI
  • Dr. Caroline Kelly, Head of Technology Strategy – CPI

Medicines Manufacturing Innovation Centre: Grand Challenge Overview

  • Dr. Barrie Cassey, Grand Challenge Lead – CPI
  • Dr. Dave Berry, Grand Challenge and Digital Strategy Lead – CPI

Panel discussion hosted by Katie Murray, Technology Director, CPI

Panellists include:

  • Dr. Barrie Cassey, Grand Challenge Lead, CPI
  • Dr. Marcus Cook, Head of Engineering, Exactmer
  • Terry Reed, Director Business Development, Astra Zeneca

Host Bio:

Neil is a seasoned business development professional with over 20 years’ experience from academia and the pharmaceutical & chemical industries working across Europe in Denmark, Germany, Austria, and the UK. Prior to joining CPI, he has held senior leadership roles in commercial, technical, and R&D teams at academic institutions, SME and multinational organisations including the University of Vienna, Loba Feinchemie and most recently Johnson Matthey.

Neil joined CPI in 2019 and as Business Development Director is responsible for identifying, developing, and delivering new business partnerships and opportunities aligned with the Medicines Manufacturing Innovation Centre’s technology strategy. Neil holds a Doctorate in Organic Chemistry from the University of Vienna, is a Chartered Chemist, a member of the Royal Society of Chemistry and active STEM ambassador.

He has a genuine passion for scientific innovation, cultivating meaningful partnerships and making strategic connections across industry and academia to promote collaboration and drive greater societal benefits.

Additional Speakers/Panellists

Dr. Sam Neill

Dr. Sam Neill

Business Development Director - CPI’s Medicines Manufacturing Innovation Centre

CPI Pharma Capabilty Overview:

Sam is a proactive and dynamic business development professional with over 19 years’ experience and is part of the team at CPI’s Medicines Manufacturing Innovation Centre, but also works closely with colleagues in our Biologics and Formulations business units.

Sam’s current role involves working with leading bio and pharmaceutical partners to overcome critical challenges around the large-scale synthesis of oligonucleotides (short stretches of synthetic DNA or RNA) and lipid nanoparticle (LNP) delivery systems that mark a paradigm shift in our ability to effectively treat a wide range of diseases and to protect populations from viruses via the tried and tested ‘Grand Challenge’ model.

Sam holds a PhD in Biological Sciences from the University of Auckland, a BSc (Hons) in Biology from Newcastle University and a BTEC HNC in Business and Finance from Northumbria University.

Dr. Caroline Kelly

Dr. Caroline Kelly

Head of Technology Strategy, Formulation

CPI Pharma Capabilty Overview:

Dr Caroline Kelly earned her degree and PhD in Chemistry from University of Cambridge, UK, and has over 15 years’ experience in the chemical industry before joining CPI in 2016.

Her early career included technical roles in formulation science and product development at large corporates, such as Esso, ICI, and Croda, and latterly a UK start-up, giving her a wide breadth of cross-sector formulation knowledge and experience.  She then moved into a customer-facing role for a UK chemical distributor, being responsible for driving the technical development and growth of a portfolio of surfactants and blended products.

She joined CPI to manage a programme of strategic partnership projects between academia, industry, and supply chain partners to build new capability as part of the grant to develop CPI’s National Formulation Centre to ultimately support companies active in formulation within the UK, including capability to support the process development and scale-up of nanotherapeutics.  Her current role is to develop and lead the technology strategy for formulation within CPI.

Dr. Barrie Cassey

Dr. Barrie Cassey

Grand Challenge Lead - CPI

Medicines Manufacturing Innovation Centre: Grand Challenge Overview

Barrie joined MMIC in early 2021 as a Grand Challenge Lead, with responsibility for launching and delivering our oligonucleotide manufacturing challenge.

Prior to MMIC, he spent 21 years working for GSK in pharmaceutical manufacturing, mostly in technical leadership roles, including over 10 years as Technical Director for a manufacturing site.

Barrie holds a BSc in Biotechnology from the University of Birmingham and PhD from the University of Sheffield.

Dr. Dave Berry

Dr. Dave Berry

Grand Challenge and Digital Strategy Lead (Medicines Manufacture) CPI

Medicines Manufacturing Innovation Centre: Grand Challenge Overview

Dave leads the Medicines Manufacturing Innovation Centre’s ‘Just in Time Clinical Pharmacy’ project and the Centres’ Digital Strategy. He started his career as a pharmacist for the NHS specialising in oncology, completed his PhD and moved to AstraZeneca to develop novel cancer treatments.

After his time at AZ he led a research group at Durham University and set up the Complex Powders facility in the National Formulation Centre. Dave is passionate about collaborative innovation and leveraging digital technology to drive the effective development of new medicines.

Dr. Katie Murray

Dr. Katie Murray

PANEL HOST: Technical Director Medicines Manufacturing Innovation Centre - CPI

Panel discussion – Host

Katie is a chemical engineer with over 25 years’ experience in the pharmaceutical industry. She started her career in process development and scale-up roles with both Merck and Co. in the US and AstraZeneca in the UK, before moving to technical leadership roles in the deployment of technology into large capital projects, also at AstraZeneca. Her expertise covers both drug substance and drug product development and manufacture.

At the start of 2020 Katie joined the Centre for Process Innovation’s Medicines Manufacturing Innovation Centre (MMIC). This is a cross industry-academia-UK government collaboration to drive the adoption of more efficient, cost-effective and environmentally friendly technology to increase patient access to medicines and reduce the manufacturing carbon footprint, through the execution of ambitious, transformational Grand Challenges. As the Technical Director for MMIC, she is responsible for leading the development and delivery of the technology strategy and has accountability for the Grand Challenge portfolio.

Katie has a PhD in Chemical Engineering from Cambridge University, an MSc in Biochemical Engineering from UCL and a BSc in Biochemistry from Oxford Uni. She is also a fellow of ICHEME (FICHEME).

Dr. Marcus Cook

Dr. Marcus Cook

Head of Engineering, Exactmer

Panel discussion

Marcus joined Exactmer in October 2020 as the head of the engineering. Prior to this, he worked as a research engineer at Concrete Canvas a fast-growing UK SME and helped set up a 2nd generation manufacturing line for their bespoke cement filled mats. After that, he spent a year at GEO Specialty Chemicals as a Development Chemist in the methacrylate side of the plant. In 2018, he completed a PhD in Chemical Engineering from Imperial College under the supervision of Professor Livingston (Exactmer, CEO).

Terry Reed

Terry Reed

Director of Business Development, AstraZeneca

Panel discussion

Terry has worked in the pharmaceutical industry for over 15 years. He has specific responsibility for the enhancement of AstraZeneca’s Pharmaceutical Technology and Development capabilities, by enabling access to the best external science, technology, and innovation.

In AstraZeneca Terry has also been instrumental in introducing new technology and building capabilities across a number of domains and disciplines. Prior to joining AstraZeneca, Terry was Director of Global Commercial Development at Pharmagene. In all Terry has more than 25 years commercial experience in the life science sector, having also held business development and management positions at Oxford Gene Technology, De Novo Pharmaceuticals, Applied Biosystems, Amersham and Millipore.